<DOC>
	<DOCNO>NCT00215904</DOCNO>
	<brief_summary>The propose experiment evaluate effect NMDA receptor full agonist D-serine ( ~2g/day ) persistent symptom Parkinson 's Disease antiparkinsonian drugs-induced dyskinesia . D-serine use add-on therapy on-going medication receive Parkinson 's Disease patient . The rational study stem observation make pervious clinical trial schizophrenia patient , demonstrate D-serine adjuvant treatment result in:1 ) improvement parkinsonian side effect induce antipsychotic drug 2 ) improvement depression negative ( i.e apathy , blunt effect , anhedonia ) symptoms similar symptom encounter Parkinson 's Disease . The study crossover design accordance patient receive , random order D-serine placebo 6 week period . Thus , participant opportunity receive experimental treatment .</brief_summary>
	<brief_title>D-serine Adjuvant Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>PD diagnosis â‰¥2 UPDRS item 32,33 receive treatment Ldopa alone combination antiparkinsonian medication . current previous history neurological disorder unstable medical condition renal pathology pregnant female patient exclude</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>